Disclosed is a process for preparing a 6-chloro-2,5-dicarbonamido phenol compounds comprising a step employing a 2-alkyl-6-aminobenzoxazole to form a 2-alkyl-6-amino-7-chlorobenzoxazole in which the 2-alkyl group is unbranched at the .alpha. carbon. It also provides intermediate compounds useful in the process. The process provides a simple and safe way to prepare 6-chloro-2,5-dicarbonamido phenol compounds in good yield.

A process for the recovery of a Lewis acid from a reaction mixture (I) which has been obtained in the hydrocyanation of an olefinically unsaturated compound to a nitrile which has a miscibility gap with water under certain pressure and temperature conditions, in the presence of a catalyst system comprising a Lewis acid and a complex compound. The method comprises a) removing the complex compound from mixture (I) to give a mixture (II), b) adding water to mixture (II) and placing mixture (II) und...

A method for purifying N-(2-hydroxyethyl)-2-pyrrolidone (HEP) is disclosed. The method comprises crystallizing crude HEP to produce HEP crystals and a mother liquor, and separating the HEP crystals from the mother liquor. In one method of the invention, crystallization is induced by adding an HEP seed crystal to the crude HEP. In a preferred method, the crystallization is performed in the presence of 1 4 wt. % of added water. HEP can be successfully crystallized to a purity greater than 99.9%.

Compounds of formula (I) ##STR00001## wherein R.sub.1 or R.sub.2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L.sub.2 and L.sub.3, to a heteroaromatic core, and X, X', Y, Y', Z, Z', R.sub.1, R.sub.2, R.sub.3, R.sub.3a, R.sub.3b, R.sub.4, R.sub.5, L, L.sub.2, and L.sub.3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions com...

Compounds of formula (I): ##STR00001## wherein: X represents oxygen or sulphur or a group CH.sub.2 or ##STR00002## R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined in the description, A represents an alkylene chain as defined in the description, B represents alkyl or alkenyl substituted by a group ##STR00003## or R.sup.9, or B represents a group ##STR00004## or R.sup.9, D represents a benzene, pyridine, pyrazine, pyrimidine or pyridazine nucleus. Medicaments

The present invention relates to a process for preparing compounds of the formula (I) ##STR00001## where R is H or F, by (a) reacting a compound of the formula (II) ##STR00002## where X is halogen, mesylate or tosylate with a thiocyanate, (b) reacting the resultant product with H.sub.2S or one of its salts to give a dithiocarbamate, and (c) reacting the dithiocarbamate with acetaldehyde, chloroacetaldehyde or an acetal thereof, and further relates to intermediates used in this process.

Compositions and methods for determining the presence or concentration of glucose in a sample which may also contain an alpha-hydroxy acid or a beta-diketone. The method uses a compound having at least two recognition elements for glucose, oriented such that the interaction between the compound and glucose is more stable than the interaction between the compound and the alpha-hydroxy acid or beta-diketone, such that the presence of the alpha-hydroxy acid or the beta-diketone does not substantial...

Compounds of the Formula: ##STR00001## are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervo...

The present invention relates to a class of compounds represented by the Formula I ##STR00001## or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub.v.beta..sub.3 and/or the .alpha..sub.v.beta..sub.5 integrin without significantly inhibiting the .alpha..sub.v.beta..sub.6 integrin.

Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds, pharmaceutical compositions and medical devices containing such compounds and methods utilizing such compounds in the treatment of various medical conditions.